Was the Heartflow (HTFL) director’s share sale under a Rule 10b5-1 plan?

Yes. The filing explains the sale was executed under a Rule 10b5-1 trading plan. Julie A. Cullivan adopted this pre-arranged plan on September 12, 2025, which allowed the February 5, 2026 transaction to occur according to preset instructions.

Heartflow director sells 8,000 shares in plan trade

Heartflow, Inc. director Julie A. Cullivan reported a planned stock sale.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Heartflow, Inc. director Julie A. Cullivan reported a planned stock sale. On February 5, 2026, she sold 8,000 shares of Common Stock of Heartflow at $27.32 per share, in an open-market transaction.

The filing states this trade was carried out under a pre-arranged Rule 10b5-1 trading plan that she adopted on September 12, 2025. After the sale, she continued to hold 36,413 shares of Heartflow common stock in direct ownership.

Insider Trade Summary

Net Seller: 8,000 shares

Net Sell 1 txn

Insider Cullivan Julie A

Role Director

Sold 8,000 shs ($219K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,000	$27.32	$219K

Holdings After Transaction: Common Stock — 36,413 shares (Direct)

Footnotes (1)

F1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Heartflow (HTFL) director Julie A. Cullivan report in this Form 4?

Julie A. Cullivan reported selling 8,000 shares of Heartflow common stock. The transaction occurred on February 5, 2026, at $27.32 per share, and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.

How many Heartflow (HTFL) shares did the director sell and at what price?

She sold 8,000 shares of Heartflow common stock at a price of $27.32 per share. This was a single reported sale transaction on February 5, 2026, as disclosed in the Form 4 insider trading report.

How many Heartflow (HTFL) shares does Julie A. Cullivan hold after the sale?

Following the reported sale, Julie A. Cullivan beneficially owned 36,413 shares of Heartflow common stock. The Form 4 indicates these remaining shares are held with direct ownership after the February 5, 2026 transaction.

What is the significance of the transaction code “S” in the Heartflow (HTFL) Form 4?

The transaction code “S” indicates an open-market or private sale of securities. In this case, it identifies Julie A. Cullivan’s February 5, 2026 sale of 8,000 Heartflow common stock shares at $27.32 per share as a sale transaction.

What is Julie A. Cullivan’s role at Heartflow (HTFL) according to the filing?

The Form 4 identifies Julie A. Cullivan as a director of Heartflow, Inc. She is not marked as an officer or 10% owner in the filing, which specifically checks the box for her role as a director only.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/06/2026 - 09:42 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cullivan Julie A

(Last)

(First)

(Middle)

C/O HEARTFLOW, INC.

331 E. EVELYN AVENUE

(Street)

MOUNTAIN VIEW

94041

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Heartflow, Inc. [ HTFL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/05/2026		S⁽¹⁾		8,000	D	$27.32	36,413	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

	/s/ Nga Van, by power of attorney	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR